Heart transplantation for COVID-19 myopathy in the United States

Evidence on characteristics and outcomes of patients undergoing heart transplantation for coronavirus disease 2019 (COVID-19) associated cardiomyopathy is limited to case reports. Of all 6,332 patients aged ≥18 years undergoing heart transplantation from July 2020 through May 2022 in the United Netw...

Descripción completa

Detalles Bibliográficos
Autores principales: Gill, George, Roach, Amy, Rowe, Georgina, Emerson, Dominic, Kobashigawa, Jon, Lobo, Errol P., Esmailian, Fardad, Bowdish, Michael E., Chikwe, Joanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: ished by Elsevier Inc. on behalf of International Society for Heart and Lung Transplantation. 2023
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9533645/
https://www.ncbi.nlm.nih.gov/pubmed/36682895
http://dx.doi.org/10.1016/j.healun.2022.09.020
Descripción
Sumario:Evidence on characteristics and outcomes of patients undergoing heart transplantation for coronavirus disease 2019 (COVID-19) associated cardiomyopathy is limited to case reports. Of all 6,332 patients aged ≥18 years undergoing heart transplantation from July 2020 through May 2022 in the United Network for Organ Sharing database, 12 (0.2%) patients had COVID-19 myocarditis and 98 (1.6%) patients with the same level of care had non-COVID-19 myocarditis. Their median age was 49 (range 19-74) years. All patients were hospitalized in the intensive care unit and 92.7% (n = 102) were on life support prior to transplantation. No patients with COVID-19 myocarditis required ventilation while waitlisted. Survival free from graft failure was 100% among COVID-19 patients and 88.5% among non-COVID-19 patients at a median of 257 (range 0-427) days post-transplant. These findings indicate that transplantation is rarely performed for COVID-19 related cardiomyopathy in the United States, yet early outcomes appear favorable in select patients.

Ejemplares similares